

Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations:

None

NNRTI Mutations:

None

RT Other Mutations:

K512R 100%
cons:0,930 • S519N 99%
cons:0,980 • Q524K 100%
cons:0,930 • K527E 100%
cons:0,752 • E529D 100%
cons:11,075 • A534S 99%
cons:12,267 • A554T 100%
cons:11,139 • K558R 100%
cons:12,967

Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible	doravirine (DOR)	Susceptible
zidovudine (AZT)	Susceptible	efavirenz (EFV)	Susceptible
stavudine (D4T)	Susceptible	etravirine (ETR)	Susceptible
didanosine (DDI)	Susceptible	nevirapine (NVP)	Susceptible
emtricitabine (FTC)	Susceptible	rilpivirine (RPV)	Susceptible
lamivudine (3TC)	Susceptible		
tenofovir (TDF)	Susceptible		

Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for NRTI.

No drug resistance mutations were found for NNRTI.

Drug resistance interpretation: IN

HIVDB 9.5.1 (2023-11-05)

INSTI Major Mutations:

None

INSTI Accessory Mutations:

None

IN Other Mutations:

K14R 99%
cons:0,758 • V31I 99%
cons:1,782 • S39N 97%
cons:0,702 • I60V 100%
cons:0,030 • K71KR 91,90%
cons:12,111 • I72V 100%
cons:12,111 • I84L 100%
cons:1,000 • T112V 100%
cons:12,111 • I113V 100%
cons:12,111 • T124TA 91,99%
cons:2,000 • T125AV 91,97%
cons:12,076 • V126VF 91,92%
cons:12,038 • I135V 100%
cons:0,075 • D167E 99%
cons:1,214 • K173R 100%
cons:0,002 • V201I 100%
cons:11,076 • I208L 100%
cons:10,108 • E212Q 100%
cons:10,094 • K219N 100%
cons:10,714 • N222K 100%
cons:10,714 • L234I 99%
cons:11,200 • S283G 100%
cons:10,902

Integrase Strand Transfer Inhibitors	
bictegravir (BIC)	Susceptible
cabotegravir (CAB)	Susceptible
dolutegravir (DTG)	Susceptible
elvitegravir (EVG)	Susceptible
raltegravir (RAL)	Susceptible

Mutation scoring: IN

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for INSTI.